GlassScriptPhysician profile
Mohammed S Bukari
NPI 1487802385
$36,081.33
in general payments reported to CMS, 2019-2025
58 companies · $11K in 2025
The $11K reported for 2025 was more than what 89% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,469 · 2020: $359 · 2021: $1,617 · 2022: $12K · 2023: $3,811 · 2024: $3,967 · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $13K · Food and Beverage: $3,717 · Travel and Lodging: $644 · Education: $582.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $13,345.00 |
| Food and Beverage | $3,717.39 |
| Travel and Lodging | $643.61 |
| Education | $581.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $7,207.70 | 2019-2025 | |
| Agios Pharmaceuticals, INC. | $6,535.68 | 2019-2025 | Pyrukynd |
| Genentech, INC. | $4,840.58 | 2022 | |
| Novartis Pharmaceuticals Corporation | $3,065.56 | 2022-2025 | |
| Sobi, INC | $2,880.29 | 2023-2025 | |
| Seagen INC. | $2,552.36 | 2019-2025 | |
| Stemline Therapeutics INC. | $2,207.69 | 2019-2025 | Elzonris |
| Morphosys, US INC. | $1,448.45 | 2021 | |
| Astellas Pharma US INC | $861.82 | 2019-2025 | Cresemba, Xtandi, Padcev |
| E.R. Squibb & Sons, L.L.C. | $615.72 | 2019-2025 | Opdualag, Opdivo |
| Pfizer INC. | $510.39 | 2019-2025 | |
| Daiichi Sankyo INC. | $408.36 | 2022-2025 | Vanflyta, Injectafer, Datroway |
| Janssen Biotech, INC. | $228.13 | 2019-2025 | Erleada, Tecvayli, Rybrevant |
| Glaxosmithkline, LLC. | $217.52 | 2021-2025 | Ojjaara, Blenrep |
| Celgene Corporation | $180.03 | 2019-2025 | Reblozyl, Opdivo, Opdualag |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammed Bukari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.